Liquidia Settled Six Lawsuits With United Therapeutics

The pharmaceutical company agreed to pay $380.7 million to resolve ongoing patent and antitrust litigation.

Updated on Oct. 14, 2026 in Healthcare

Bold flat-color editorial illustration featuring a geometric molecular structure in navy, cream, and red, representing pharmaceutical legal settlement. — Liquidia settled six lawsuits with United Therapeutics, agreeing to a $380.7 million payment to resolve long-standing patent and antitrust litigation. AI Illustration. Upload story photo >

Live Poll

Should pharmaceutical companies prioritize settling patent litigation to maintain patient access to medications?

Liquidia has reached a global settlement agreement with United Therapeutics to resolve six lawsuits, ending years of legal disputes. The agreement includes a total payment of $380.7 million to be distributed through 2027.

Why it matters

The settlement removes significant legal uncertainty for Liquidia, allowing the company to focus on its YUTREPIA drug program. It also clarifies the market path for the treatment of pulmonary arterial hypertension.

Liquidia will pay $175 million initially, followed by two $72.7 million installments and a $60.3 million antitrust litigation settlement. The company reported $222.7 million in third-quarter YUTREPIA net product sales.

The players

Liquidia

This is a biopharmaceutical company focused on the development and commercialization of products for pulmonary hypertension.

United Therapeutics

This is a biotechnology company that develops therapies for chronic and life-threatening conditions, including pulmonary arterial hypertension.

The details

As part of the resolution, Liquidia submitted a supplement to remove the PH-ILD indication from its YUTREPIA drug label and terminated its promotional agreement for Treprostinil Injection. The firm intends to fund these payments through its ongoing drug sales and existing cash reserves.

A Delaware federal court issued a patent infringement ruling on September 30, 2026.
The global settlement agreement was announced on October 14, 2026.
Liquidia is scheduled to pay the first $72.7 million installment on January 31, 2027.
A second $72.7 million payment is due on April 30, 2027.

Market Landscape

This settlement resolves the long-running patent and antitrust litigation between the two firms that previously hampered market operations. It allows Liquidia to stabilize its corporate trajectory and maintain its competitive stance in the hypertension medication sector.

Customers relying on YUTREPIA for pulmonary arterial hypertension will see the medication remain available as planned. The settlement ensures continued product access while allowing Liquidia to move forward with its other clinical programs.

The takeaway

This resolution provides a clear financial and operational path forward for Liquidia after years of legal volatility. Investors should monitor how the company balances its upcoming installment payments with its ongoing drug development programs.